
Long COVID, or post-acute sequelae of SARS-CoV-2 (PASC), affects an estimated 10–20% of individuals following SARS-CoV-2 infection. Despite its substantial global burden, the pathophysiological mechanisms remain incompletely understood. This systematic review aimed to synthesize available evidence on viral persistence, immune activation, and histopathological changes across multiple organ systems, drawing from studies of individuals with Long COVID as well as broader post-acute cohorts, autopsy investigations, and case-based reports relevant to Long COVID pathophysiology. Following PRISMA guidelines and holding a PROSPERO registration (CRD420261403869), a systematic literature search was conducted across PubMed, Scopus, EMBASE, and Cochrane CENTRAL. Eligible reports were stratified as (A) symptom-defined Long COVID assessed at or after 12 weeks, (B) post-acute or mixed populations without a consistently confirmed Long COVID definition or timing, (C) autopsy studies, and (D) isolated case/fetal reports. Findings were synthesized narratively by specimen, assay target, and unit of analysis. JBI checklists were used for item-level appraisal, not as certainty-of-evidence ratings. Forty-five reports were included: 16 in stratum A, 23 in stratum B, three autopsy studies, and three isolated case/fetal reports. SARS-CoV-2 genomic RNA, viral proteins, and markers compatible with recent viral activity were reported in selected tissue and blood compartments, but detection varied with population selection, timing, specimen, and assay. No included study established replication competence by recovery of infectious virus. Histopathological abnormalities included inflammatory infiltrates, fibrosis, and vascular injury; however, causal attribution to Long COVID was limited by acute disease severity, biopsy indication, comorbidity, and incomplete comparator data. A single participant total was not reported because of overlapping cohorts, repeated sampling, and outcome-specific denominators. The review supports biological heterogeneity after SARS-CoV-2 infection, including residual viral material, immune dysregulation, vascular injury, and maladaptive tissue repair. Organ-specific prevalence, a hierarchy of tissue tropism, replication-competent reservoirs, and superiority of antiviral or immunomodulatory treatment remain undefined. Standardized Long COVID definitions, representative cohorts, validated assays, appropriate comparators, and longitudinal studies linking biological markers to clinical outcomes are required.
Diabetes mellitus–induced erectile dysfunction (DMED) is a common male sexual disorder involving neural, vascular, and metabolic dysfunction. This study aimed to investigate the role of ferroptosis in DMED and identify key ferroptosis-related genes using multi-omics approaches. Bulk transcriptomic, proteomic, and single-cell RNA sequencing data from rat corpus cavernosum were integrated. Differential expression analysis, Scissor analysis, scWGCNA, and machine learning (LASSO and Boruta) were applied to identify core ferroptosis-related genes. Expression patterns were examined at single-cell and spatial transcriptomic levels and validated by RT-qPCR in human umbilical vein endothelial cells (HUVECs) under high-glucose conditions. Transcriptomic and proteomic analyses indicated activation of iron ion transport and ion homeostasis pathways in DMED, suggesting ferroptosis involvement. Single-cell analysis highlighted macrophages and endothelial cells as primary ferroptotic cell types. Four core genes—STOM, PLVAP, SPARC and WIPI1—were identified, with STOM upregulated and the other three downregulated in DMED. Spatial and single-cell analyses showed STOM and PLVAP predominantly localized in corpus cavernosum sinusoids. RT-qPCR confirmed their differential expression under high-glucose conditions. This study systematically implicates ferroptosis in DMED and identifies STOM, PLVAP, SPARC, and WIPI1 as potential biomarkers and therapeutic targets. Further research is needed to validate these findings in clinical cohorts and clarify their mechanistic roles in DMED pathophysiology.
Rabbit anti-T-lymphocyte globulin (ATLG; Grafalon) and rabbit anti-thymocyte globulin (ATG; Thymoglobulin) are noninterchangeable polyclonal preparations used within haploidentical hematopoietic cell transplantation (haplo-HCT) platforms. Their immunogens, antibody repertoires and nominal dose scales differ, but direct comparative clinical evidence is sparse. This narrative review examines product-specific evidence, active-antibody exposure and the unresolved dosing of serotherapy combined with post-transplant cyclophosphamide (PTCy). The available propensity-matched haploidentical comparison used Thymoglobulin 6 mg/kg and ATLG 10 mg/kg; the latter was substantially below ATLG totals commonly used even in matched-donor transplantation. Its infection and chronic graft-versus-host disease findings therefore cannot establish intrinsic product differences. PTCy-based and serotherapy-based platforms coexist, including outside Western centers, and neither the optimal rabbit-globulin dose nor the optimal PTCy dose in combined regimens is established. Recipient absolute lymphocyte count (ALC), infusion timing and graft cellularity modify exposure. ATLG-specific ALC studies support this association, but prospectively validated ATLG ALC-based dosing models remain needed. Product, conditioning, graft source, PTCy, mycophenolate mofetil and other immunosuppression should be evaluated as one protocol. Clinical use should follow product-specific, locally validated regimens while trials define exposure targets and the net benefit of combination prophylaxis.
Pancreatic cancer, a highly malignant tumor, poses a severe threat to human health, and widely applicable therapeutic targets with substantial clinical benefits remain limited. SPAG4 exhibits limited expression in normal tissues but is aberrantly activated and significantly upregulated in multiple tumors; its role in pancreatic cancer remains unclear. Multi-database bioinformatics analysis was employed to explore SPAG4’s potential function in pancreatic cancer. In vitro assays (CCK-8, colony formation, EdU, Transwell, and scratch wound healing) were performed to evaluate the effects of SPAG4 on pancreatic cancer cell phenotypes. SPAG4 upregulation in multiple tumors correlated with poor prognosis. Integrated bulk transcriptomic and single-cell RNA-seq analyses showed SPAG4 overexpression in pancreatic cancer, which was associated with poor survival and adverse clinicopathological features. Functional enrichment analysis based on SPAG4-associated transcriptomic alterations suggested potential involvement in oncogenic processes, including cellular metabolism, genomic maintenance, cell-cycle progression, intercellular adhesion, growth regulation, and MAPK/ERK signaling. SPAG4 expression was also associated with TIMER-estimated immune infiltration. In vitro assays showed that SPAG4 modulation altered pancreatic cancer cell proliferation, migration, and invasion.
Diabetic kidney disease (DKD) is characterized by chronic metabolic and inflammatory stress and is clinically associated with complicated urinary infection. However, the renal programs that are reproducibly altered in DKD and uropathogenic Escherichia coli (UPEC) pyelonephritis remain incompletely defined. We reanalyzed murine snRNA-seq datasets (GSE184652 for DKD; GSE296327 for UPEC). Differential expression was tested via proximal-tubule (PT) pseudobulk analysis. Inflammation was evaluated using Hallmark/KEGG enrichment. Lpl function was validated in DKD-PT cells via overexpression assays (CCK-8, qRT-PCR, ELISA). UPEC showed positive inflammation-union enrichment in all seven eligible renal compartments, whereas DKD showed five selective, bidirectional compartment-direction signals. In PT, UPEC positively enriched all six inflammatory Hallmarks while DKD negatively enriched interferon-gamma and interferon-alpha responses. Seven genes were cohort-wise significant and direction-concordant. Lpl was downregulated in DKD and UPEC, localized descriptively to PT nuclei, and belonged to PPAR, cholesterol and glycerolipid metabolism pathways. Nevertheless, the minimum directional gene-level conjunction q was 0.133, WGCNA quality targets were not achieved. Functionally, LPL-1 overexpression significantly inhibited cell proliferation in both uPTECs and DKD-PTECs. Furthermore, LPL-1 overexpression markedly suppressed the transcriptional levels and protein secretion of key inflammatory cytokines, including TNF-α, IL-1β, and IL-6, in both cell types. DKD and UPEC exhibit divergent renal inflammatory programs. Lpl links tubular lipid handling to inflammation and may protect against DKD-associated tubular injury, warranting further validation.